K Number
K162268
Device Name
Senographe Pristina
Manufacturer
Date Cleared
2016-11-03

(83 days)

Product Code
Regulation Number
892.1715
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
Senographe Pristina generates digital mammographic images that can be used for screening and in the diagnosis of breast cancer. Senographe Pristina is intended to be used in the same clinical applications as traditional mammographic screenfilm systems.
Device Description
Senographe Pristina is a new Full Field Digital Mammography (FFDM) system. The system consists of an X-ray image acquisition system dedicated to breast imaging and of a control station for image acquisition, processing and display. The image acquisition system includes a Cesium lodine digital detector, x-ray tube, integrated high voltage generator, compression paddles. The control station provides a touch-screen user interface to control image acquisition, image processing, and image transfer.
More Information

P990066/S021

Not Found

No
The summary describes a standard digital mammography system with image processing capabilities, but there is no mention of AI, ML, or related concepts like deep learning or neural networks. The performance studies focus on image quality and clinical evaluation by radiologists, not on the performance of an AI/ML algorithm.

No
The device is described as generating digital mammographic images for screening and diagnosis of breast cancer, which are diagnostic purposes, not therapeutic.

Yes
The device is explicitly stated to be used "in the diagnosis of breast cancer," which clearly indicates a diagnostic function.

No

The device description explicitly states it includes hardware components such as an X-ray image acquisition system, digital detector, x-ray tube, high voltage generator, and compression paddles.

Based on the provided information, this device is not an IVD (In Vitro Diagnostic).

Here's why:

  • IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
  • Device Function: The description clearly states that Senographe Pristina is an X-ray imaging system used to generate digital mammographic images. It works by using X-rays to create images of the breast.
  • No Sample Analysis: The device does not analyze biological samples taken from the patient. It directly images the anatomical site (breast) using an external energy source (X-rays).

Therefore, Senographe Pristina falls under the category of a medical imaging device, not an in vitro diagnostic device.

N/A

Intended Use / Indications for Use

Senographe Pristina generates digital mammographic images that can be used for screening and in the diagnosis of breast cancer. Senographe Pristina is intended to be used in the same clinical applications as traditional mammographic screen-film systems.

Product codes

MUE

Device Description

Senographe Pristina is a new Full Field Digital Mammography (FFDM) system. The system consists of an X-ray image acquisition system dedicated to breast imaging and of a control station for image acquisition, processing and display. The image acquisition system includes a Cesium Iodine digital detector, x-ray tube, integrated high voltage generator, compression paddles. The control station provides a touch-screen user interface to control image acquisition, image processing, and image transfer.

Mentions image processing

Yes

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

X-ray

Anatomical Site

Breast

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies

Complete Image Quality Bench Performance testing was completed showing appropriate performance. A Clinical image evaluation was performed showing that image quality of Senographe Pristina in a clinical setting is good as assessed by expert radiologists. Compliance was demonstrated against applicable safety and performance standards. Successful System and Software verification and validation.

Key Metrics

Not Found

Predicate Device(s)

Senographe Essential (P990066/S021)

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 892.1715 Full-field digital mammography system.

(a)
Identification. A full-field digital mammography system is a device intended to produce planar digital x-ray images of the entire breast. This generic type of device may include digital mammography acquisition software, full-field digital image receptor, acquisition workstation, automatic exposure control, image processing and reconstruction programs, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II (special controls). The special control for the device is FDA's guidance document entitled “Class II Special Controls Guidance Document: Full-Field Digital Mammography System.”See § 892.1(e) for the availability of this guidance document.

0

Image /page/0/Picture/1 description: The image shows the seal of the Department of Health & Human Services - USA. The seal is circular, with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. In the center of the seal is a stylized image of three human profiles facing right, stacked on top of each other. The profiles are connected by a flowing line that resembles a ribbon or wave.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

November 3, 2016

GE Healthcare % Mr. Gregory Pessato Regulatory Affairs Program Manager 283 rue de la Miniere Buc, 78530 FRANCE

Re: K162268

Trade/Device Name: Senographe Pristina Regulation Number: 21 CFR 892.1715 Regulation Name: Full-field digital mammography system Regulatory Class: II Product Code: MUE Dated: August 16, 2016 Received: August 17, 2016

Dear Mr. Pessato:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

1

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Michael D.'Hara

For

Robert Ochs, Ph.D. Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

Enclosure

2

Indications for Use

510(k) Number (if known)

K162268

Device Name Senographe Pristina

Indications for Use (Describe)

Senographe Pristina generates digital mammographic images that can be used for screening and in the diagnosis of breast cancer. Senographe Pristina is intended to be used in the same clinical applications as traditional mammographic screenfilm systems.

X Prescription Use (Part 21 CFR 801 Subpart D)

| Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

3

Image /page/3/Picture/0 description: The image shows the General Electric (GE) logo. The logo consists of the letters 'GE' in a stylized, cursive font, enclosed within a circular frame. The color of the logo is a light blue.

510(k) Summary

In accordance with 21 CFR 807.92 the following summary of information is provided:

Date:August 5, 2016
Submitter:GE Medical Systems SCS
Primary Contact Person:Gregory Pessato
Regulatory Affairs Program Manager
GE Healthcare
283 RUE DE LA MINIERE
78530 BUC - FRANCE
Phone : + 33 1 30 70 93 16
Email : GregoryPessato@ge.com
Secondary Contact
Person:Diane Uriell
Director of Regulatory Affairs, XR and Women's Health
GE Healthcare
Atlanta GA
Phone +1 262 290 8212
Email:Diane.Uriell@ge.com .
Device Trade Name:Senographe Pristina
Common/Usual Name:Full-field digital mammography system
Classification Names:Full-field digital mammography system
Class II CFR 892.1715
Product Code:MUE
Predicate Device(s):Senographe Essential (P990066/S021)
Device Description:Senographe Pristina is a new Full Field Digital Mammography (FFDM)
system. The system consists of an X-ray image acquisition system
dedicated to breast imaging and of a control station for image acquisition,
processing and display. The image acquisition system includes a Cesium
lodine digital detector, x-ray tube, integrated high voltage generator,
compression paddles. The control station provides a touch-screen user
interface to control image acquisition, image processing, and image
transfer.
Indications for Use:Senographe Pristina generates digital mammographic images that can be
used for screening and in the diagnosis of breast cancer. Senographe
Pristina is intended to be used in the same clinical applications as
traditional film-based mammographic systems.
Comparison Of
Technological
Characteristics With The
Predicate Device:Senographe Pristina uses the same fundamental technology as
Senographe Essential in terms of image acquisition (X-ray tube, detector,
image processing). Senographe Pristina includes a dual track anode with
silver filter, a Cesium lodine detector
Senographe Pristina was redesigned using actualized components and
improved ergonomics. In particular Senographe Pristina was designed
with:
Improved patient ergonomics (rounded shapes, soft armrests, thin
breast support) for improved patient comfort;
Improved technologist ergonomics (large workspace, sliding implant /
small breast paddle) for better access to patient and eased patient
positioning;
A new gantry motorization with independent compression and X-ray
tube head angulation for upgradability to 3D;
Integrated X-ray generator for reduced footprint.
Determination of
Substantial Equivalence:Senographe Pristina has the same indications for use as its predicate
device. It uses the same fundamental technology as Senographe Essential.
Differences between Senographe Pristina do not raise new questions of
safety and effectiveness.
The impact of differences between the predicate and new device has been
assessed using applicable FDA Guidance and Standards.
In particular the following testing was performed:
Complete Image Quality Bench Performance testing was completed
showing appropriate performance.
A Clinical image evaluation was performed showing that image quality
of Senographe Pristina in a clinical setting is good as assessed by expert
radiologists.
Compliance was demonstrated against applicable safety and
performance standards. Successful System and Software verification and validation.
Conclusion:Senographe Pristina is substantially equivalent to its predicate device
Senographe Essential.

4

Image /page/4/Picture/1 description: The image shows the logo for General Electric (GE). The logo is a blue circle with the letters "GE" in a stylized font in the center. The letters are also blue, and they are surrounded by a white border. The logo is simple and recognizable, and it is a well-known symbol of the General Electric company.